Exploratory results from a phase 2 trial in IgA nephropathy. Complement looks like a promising place area to target IgA. And these are going after C5

Exploratory results from a phase 2 trial in IgA nephropathy. Complement looks like a promising place area to target IgA. And these are going after C5